PB1878: CROSS‐TRIAL ANALYSIS OF FIXED‐DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Autor:	Barrientos, J. C., Barr, P. M., Mato, A. R., Tam, C. S., Ghia, P., Moreno, C., Kay, N. E., Siddiqi, T., Szafer‐Glusman, E., Zhou, C., Neumayr, L., Krigsfeld, G., Wierda, W. G., Shanafelt, T.
Zdroj:	HemaSphere; 2022 Supplement 3, Vol. 6, p1758-1759, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text